73 related articles for article (PubMed ID: 32774500)
21. Distinctive genomic characteristics in
He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types.
Gong Z; Yang Y; Zhang J; Guo W
Cancer Biol Med; 2021 May; 18(4):1080-91. PubMed ID: 33960179
[TBL] [Abstract][Full Text] [Related]
23. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
Giustini N; Bazhenova L
Lung Cancer (Auckl); 2021; 12():21-34. PubMed ID: 33790679
[TBL] [Abstract][Full Text] [Related]
24. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
[No Abstract] [Full Text] [Related]
25. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
26. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
Mody K; Starr J; Saul M; Poorman K; Weinberg BA; Salem ME; VanderWalde A; Shields AF
J Gastrointest Oncol; 2019 Dec; 10(6):1099-1109. PubMed ID: 31949927
[TBL] [Abstract][Full Text] [Related]
27. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.
Arora S; Velichinskii R; Lesh RW; Ali U; Kubiak M; Bansal P; Borghaei H; Edelman MJ; Boumber Y
Adv Ther; 2019 Oct; 36(10):2638-2678. PubMed ID: 31410780
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
[TBL] [Abstract][Full Text] [Related]
29. Challenges towards the realization of individualized cancer vaccines.
Türeci Ö; Löwer M; Schrörs B; Lang M; Tadmor A; Sahin U
Nat Biomed Eng; 2018 Aug; 2(8):566-569. PubMed ID: 31015635
[No Abstract] [Full Text] [Related]
30. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
31. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Qiu H; Zmina PM; Huang AY; Askew D; Bedogni B
Cancer Lett; 2018 Oct; 434():144-151. PubMed ID: 30036609
[TBL] [Abstract][Full Text] [Related]
34. Lynch syndrome - cancer pathways, heterogeneity and immune escape.
Seth S; Ager A; Arends MJ; Frayling IM
J Pathol; 2018 Oct; 246(2):129-133. PubMed ID: 30027543
[TBL] [Abstract][Full Text] [Related]
35. PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.
Davis TB; Yang M; Schell MJ; Wang H; Ma L; Pledger WJ; Yeatman TJ
Sci Rep; 2018 Jun; 8(1):9296. PubMed ID: 29915291
[TBL] [Abstract][Full Text] [Related]
36. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S; Perrone F; Miceli R; Ascierto PA; Locati LD; Bergamini C; Granata R; Alfieri S; Resteghini C; Galbiati D; Busico A; Paielli N; Patuzzo R; Maurichi A; Gallino G; Ruggeri R; Mariani L; Palla M; Licitra L; Bossi P
Eur J Cancer; 2018 Jul; 97():7-15. PubMed ID: 29734047
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
39. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY; Seier K; Ostrovnaya I; Regazzi AM; Kania BE; Moran MM; Cipolla CK; Bluth MJ; Chaim J; Al-Ahmadie H; Snyder A; Carlo MI; Solit DB; Berger MF; Funt S; Wolchok JD; Iyer G; Bajorin DF; Callahan MK; Rosenberg JE
J Clin Oncol; 2018 Jun; 36(17):1685-1694. PubMed ID: 29489427
[TBL] [Abstract][Full Text] [Related]
40. Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
Sirkisoon SR; Carpenter RL; Rimkus T; Anderson A; Harrison A; Lange AM; Jin G; Watabe K; Lo HW
Oncogene; 2018 May; 37(19):2502-2514. PubMed ID: 29449694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
